CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01217749
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:53.506840+00:00
Published At: 2015-04-16T00:00:00+00:00
Record Updated At: 2015-06-25
Results Posted At: 2015-04-16
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["B-cell Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Prolymphocyctic Leukemia", "Richter\u0027s Transformation"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2015-06-25"
protocolSection.identificationModule.nctId: "NCT01217749"
protocolSection.identificationModule.officialTitle: "An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton\u0027s Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2015-04-16"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.